Fintel reports that on January 5, 2025, BNP PARIBAS EXANE upgraded their outlook for Novo Nordisk A (NYSE:NVO) from Neutral ...

In the closing of the recent trading day, Novo Nordisk (NVO) stood at $83.34, denoting a -1.99% change from the preceding trading day.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk A/S (NYSE:NVO – Get Free Report) was upgraded by equities researchers at Sanford C. Bernstein from an “underperform” rating to a “market perform” rating in a research note issued on ...

Novo Nordisk (NVO) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock ...

Short NVO slightly under 101.15, target n/a, stop loss @ 101.44 Check the time stamp on this data. Updated AI-Generated ...

Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.

The general mood among these heavyweight investors is divided, with 50% leaning bullish and 31% bearish. Among these notable ...

Investors in Novo-Nordisk AS (Symbol: NVO) saw new options begin trading today, for the February 2025 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVO ...

The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity. NVO is a Zacks Rank #3 (Hold) stock, with a Growth Style Score of A and VGM Score ...